SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

relutrigine

PRAX·Praxis Precision Medicines, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Filed/PDUFA (NDA under priority review)
Time to market
PDUFA target action date is December 27, 2026. If approved, a U.S. launch could follow in early 2027.
Why 8/10
The next hard, dated catalyst is the FDA PDUFA target action date of December 27, 2026, roughly six weeks from today, for the relutrigine NDA in SCN2A and SCN8A DEEs. This is a binary regulatory decision on a lead asset at a company that also has a second NDA (ulixacaltamide) under review, so the impact score reflects a major value driver with a near-term binary but not a single-asset make-or-break.
Actionable Insight BULLISH

The next binary catalyst is the PDUFA decision on December 27, 2026, roughly six weeks away. Approval would likely drive a significant re-rating given no approved therapies exist for SCN2A/SCN8A DEEs, while a CRL would pressure the stock. Also watch for EMERALD study topline results in broad DEEs (Q4 2026), which could expand the addressable market.

Price Chart

Loading chart...

Executive Summary

Relutrigine (PRAX-562) is Praxis Precision Medicines' lead epilepsy asset, a sodium channel functional state modulator targeting SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), severe genetic childhood epilepsies with no approved therapies. The FDA accepted the NDA with priority review, granted Breakthrough Therapy Designation, and set a PDUFA target action date of December 27, 2026 (extended from September). The Phase 2 EMBOLD study was stopped early for efficacy, and positive results supported the submission. Praxis also has a second NDA (ulixacaltamide for essential tremor, PDUFA January 29, 2027) under review, and expects topline data from the EMERALD broad-DEE study in Q4 2026. The stock trades around $323 with a strong buy analyst consensus and a mean price target of ~$662, implying roughly 104% upside.

How It Works

Relutrigine is a sodium channel functional state modulator. In simple terms, it works by adjusting the activity of sodium channels on brain cells (neurons). In certain genetic forms of severe childhood epilepsy (SCN2A and SCN8A DEEs), mutations cause these sodium channels to malfunction, leading to excessive electrical activity and seizures. Relutrigine is designed to selectively correct that dysfunction by stabilizing the channel in its resting state, reducing runaway neuronal firing without broadly suppressing brain activity.

Trial Status

The pivotal Phase 2 EMBOLD study in SCN2A and SCN8A DEEs was stopped early for efficacy by the Data Monitoring Committee in December 2025. Positive topline results were announced, and the data served as the basis for the NDA submission. The FDA accepted the NDA with priority review in March 2026. An additional study, EMERALD, evaluating relutrigine in a broader DEE population, is ongoing with topline results expected in Q4 2026.

The Two-Sided Case

▲ Bull Case5
Relutrigine has Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from the FDA, signaling strong agency interest and potential priority review benefits.
The Phase 2 EMBOLD study was stopped early for efficacy by the Data Monitoring Committee, and positive results formed the basis of the NDA submission with priority review.
No approved therapy specifically targets SCN2A/SCN8A developmental and epileptic encephalopathies, positioning relutrigine for potential first-in-class / first-in-disease status if approved.
Analyst consensus is Strong Buy with a mean price target of $661.75 (roughly 104% upside from the current ~$323 price), and 24 of 27 analysts rate it Buy or Strong Buy.
Major institutional holders include Jupiter Topco ($1.1B), FMR/Fidelity ($776M), BlackRock ($768M), and Baker Bros. ($587M), with continued accumulation in Q3 2026.
▼ Bear Case4
The FDA extended the original PDUFA by three months (from September to December 2026), which could signal review complexity or lingering safety/efficacy questions. The extension was attributed broadly to FDA staffing issues, but uncertainty remains.
The company is pre-revenue with no approved products; if relutrigine receives a Complete Response Letter (CRL), the stock would face significant downside given its ~$8B+ market cap already prices in approval.
The EMERALD study in broad DEEs (topline due Q4 2026) is a separate readout that could disappoint, and relutrigine's label may be initially limited to narrow SCN2A/SCN8A populations.
Wedbush rates the stock Underperform, and one analyst has a Strong Sell rating, indicating dissenting views on valuation or pipeline prospects.

Upcoming Catalysts

  • PDUFA target action date: December 27, 2026 (FDA decision on approval)
  • EMERALD study topline results in broad DEEs: expected Q4 2026
  • Potential label expansion into Dravet syndrome (Rare Pediatric Disease Designation already granted)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report

Sources · 8

Hover a chip for the title
1 markets.businessinsider.com2 marketscreener.com3 nasdaq.com4 streetinsider.com5 marketwatch.com6 tipranks.com7 nasdaq.com8 streetinsider.com